The drug is osilodrostat, sold under the brand name Isturisa, and it is the first medication to directly block the final enzyme responsible for producing cortisol in the adrenal glands. On April 16, 2025, the FDA granted an expanded approval for osilodrostat to treat endogenous hypercortisolemia in adults with Cushing’s syndrome who either cannot undergo surgery or whose surgery failed to resolve the condition. Manufactured by Recordati, the drug has now been studied in more than 350 patients across multiple clinical trials, and real-world evidence shows it normalizes cortisol levels in roughly 70 percent of patients with elevated baseline readings. For people living with Cushing’s disease, a condition where a pituitary tumor drives dangerously high cortisol production, this represents a genuine shift in treatment options. This matters for brain health more than most people realize.
Chronic excess cortisol ravages the hippocampus, accelerates brain atrophy, and is linked to cognitive decline, depression, and increased dementia risk. Patients with untreated or poorly managed Cushing’s disease often present with memory problems, difficulty concentrating, and psychiatric symptoms that can mimic or worsen neurodegenerative conditions. Getting cortisol under control is not just an endocrine issue. It is a neuroprotective one. This article covers how osilodrostat works at the molecular level, what the clinical trial data actually shows, how it compares to other non-surgical options like mifepristone and pasireotide, what happened when the FDA rejected the anticipated next-generation competitor relacorilant in late 2025, and what all of this means for patients and caregivers navigating Cushing’s disease alongside cognitive concerns.
Table of Contents
- How Does the Cushing’s Disease Drug Work Without Surgery?
- What the Real-World Data Shows, and Where It Falls Short
- How Osilodrostat Compares to Other Non-Surgical Cushing’s Treatments
- What Happened to Relacorilant, and Why It Matters for Patients
- The Brain Health Connection That Cushing’s Patients Cannot Afford to Ignore
- Why Expanded FDA Approval Changes the Treatment Conversation
- What Comes Next for Non-Surgical Cushing’s Treatment
- Conclusion
- Frequently Asked Questions
How Does the Cushing’s Disease Drug Work Without Surgery?
Osilodrostat targets an enzyme called 11-beta-hydroxylase, which catalyzes the final step of cortisol biosynthesis in the adrenal gland. By blocking this specific enzyme, the drug prevents the conversion of 11-deoxycortisol into cortisol at the very last stage of production. It is the first FDA-approved medication to work through this particular mechanism, which distinguishes it from older drugs that either block cortisol’s receptor or inhibit steroidogenesis at earlier, less specific points in the pathway. Think of it as shutting off the last valve in a pipeline rather than trying to reduce pressure further upstream where you risk disrupting other hormone production. The Phase 3 LINC 3 study enrolled 137 patients with persistent or recurrent Cushing’s disease and treated them with twice-daily osilodrostat. Researchers observed rapid reductions in mean 24-hour urinary free cortisol, the gold-standard measurement for assessing cortisol overproduction.
These reductions were not fleeting. Patients showed sustained cortisol control along with improvements in clinical signs of hypercortisolism, including changes in body composition, skin fragility, and metabolic markers. A separate trial, LINC 4, confirmed these results using a more rigorous design: a 12-week randomized, double-blind, placebo-controlled period followed by a 36-week open-label extension, during which osilodrostat rapidly normalized mean urinary free cortisol in most patients and maintained the effect over time. What makes this relevant beyond endocrinology is the downstream effect on the brain. Sustained cortisol normalization has been associated in multiple studies with partial reversal of hippocampal volume loss and improvement in cognitive function. While osilodrostat trials did not specifically measure cognitive endpoints, the mechanism of action, reducing cortisol to normal physiological levels, addresses one of the most well-documented hormonal contributors to neurodegeneration.
What the Real-World Data Shows, and Where It Falls Short
Clinical trials are controlled environments. Real-world evidence fills in the gaps that trial protocols cannot cover: patients with multiple comorbidities, varied dosing practices, and the general unpredictability of treating people outside a research setting. The ILLUSTRATE study, published in 2025 in the Journal of the Endocrine Society, followed 42 patients treated with osilodrostat between May 2020 and October 2021. Of those, 34 had Cushing’s disease, five had adrenal adenoma, and three had ectopic ACTH syndrome. Among the 20 patients who entered the study with elevated urinary free cortisol, 14 achieved normalization below the upper limit of normal. That is a 70 percent efficacy rate in a real-world population, which is notable because real-world numbers are typically worse than clinical trial results, not equivalent. The most common starting dose was 2 mg twice daily, used in about 64 percent of patients. Among those who reached a stable maintenance dose, roughly two-thirds remained at that same 2 mg twice-daily level, suggesting that dose escalation was not required for the majority.
However, this is where the caveats become important. Adrenal insufficiency or glucocorticoid withdrawal syndrome occurred in 28.6 percent of patients, meaning nearly one in three experienced the opposite problem: cortisol levels dropping too low. Adrenal insufficiency can cause fatigue, dizziness, nausea, and in severe cases, adrenal crisis, which is a medical emergency. Additional adverse events occurring in more than 20 percent of patients included fatigue, nausea, and lower-extremity edema. For patients and caregivers managing Cushing’s alongside cognitive symptoms or dementia risk, this safety profile demands careful monitoring. A person whose cortisol swings between dangerously high and dangerously low is neurologically vulnerable in both directions. Low cortisol can impair alertness, worsen confusion, and trigger psychiatric disturbances just as excess cortisol can. The drug works, but it requires attentive dose titration and regular cortisol monitoring, ideally with an endocrinologist experienced in Cushing’s management.
How Osilodrostat Compares to Other Non-Surgical Cushing’s Treatments
Osilodrostat is not the only non-surgical pharmaceutical option for Cushing’s, but it occupies a distinct niche. Mifepristone, marketed as Korlym, is a glucocorticoid receptor antagonist approved specifically for hyperglycemia secondary to hypercortisolism in Cushing’s patients who are not surgical candidates. Rather than reducing cortisol production, mifepristone blocks cortisol from binding to its receptor. The clinical paradox is that cortisol levels in the blood actually rise on mifepristone, making it impossible to use standard cortisol measurements to monitor treatment effectiveness. Physicians must rely on clinical signs, glucose levels, and other indirect markers. For patients with cognitive concerns, this lack of a clear biomarker for treatment response is a real limitation.
Pasireotide, sold as Signifor, takes a different approach entirely. It is a somatostatin receptor ligand that acts at the pituitary gland, targeting the tumor that drives cortisol overproduction in Cushing’s disease specifically. Its efficacy is more modest than osilodrostat’s in head-to-head comparisons of cortisol normalization rates, and it carries a significant risk of hyperglycemia, which can be problematic for patients already dealing with metabolic dysfunction from cortisol excess. Levoketoconazole, branded as Recorlev, is a steroidogenesis inhibitor that works earlier in the cortisol production pathway than osilodrostat. It offers another option but shares the class-related concern of hepatotoxicity that has long shadowed ketoconazole-based therapies. Each of these drugs fills a role, but osilodrostat’s combination of direct enzymatic blockade at the final step, measurable cortisol reduction that clinicians can track with standard labs, and now an expanded FDA label covering all forms of endogenous Cushing’s syndrome gives it a practical edge for many patients.
What Happened to Relacorilant, and Why It Matters for Patients
Relacorilant, developed by Corcept Therapeutics, was the most anticipated next-generation drug for Cushing’s syndrome. It is a selective glucocorticoid receptor modulator, meaning it blocks cortisol’s receptor similarly to mifepristone but with one critical difference: relacorilant has no affinity for the progesterone receptor. This was supposed to solve the most troubling side effects of mifepristone, including endometrial hypertrophy, irregular vaginal bleeding, and the risk of pregnancy termination. For women of reproductive age with Cushing’s, these are not minor concerns. Clinical trials, named GRACE and GRADIENT, showed promising signals.
Patients on relacorilant experienced mean decreases of approximately 8 mmHg systolic and 5 mmHg diastolic blood pressure on 24-hour ambulatory monitoring, a meaningful cardiovascular benefit for a population already burdened with hypertension from cortisol excess. But on December 30, 2025, the FDA issued a Complete Response Letter rejecting the drug, stating it could not approve relacorilant without additional evidence of efficacy. Corcept’s stock price fell roughly 50 percent in the aftermath, and subsequent reporting from STAT News described the dispute between Corcept and the FDA as one that “runs deep.” For patients, the rejection of relacorilant narrows the non-surgical treatment landscape in the near term. Those who were waiting for a progesterone-neutral receptor antagonist will need to work with their physicians to choose among the existing options. This is particularly relevant for women managing Cushing’s who are also navigating hormonal concerns or reproductive planning. The rejection does not mean relacorilant is dead, as Corcept may pursue additional trials, but it will not be available anytime soon.
The Brain Health Connection That Cushing’s Patients Cannot Afford to Ignore
Cortisol is neurotoxic at sustained high levels. This is not speculative. Decades of research have demonstrated that chronic hypercortisolism causes hippocampal atrophy, disrupts synaptic plasticity, impairs memory consolidation, and accelerates the kind of brain volume loss typically associated with aging and neurodegeneration. Patients with Cushing’s disease frequently report cognitive fog, difficulty with short-term memory, emotional lability, and depression. These symptoms are sometimes misattributed to primary psychiatric disorders or early dementia when the underlying driver is excess cortisol. Successful treatment of Cushing’s, whether through surgery or medication, has been shown to partially reverse hippocampal atrophy and improve cognitive function in some patients, though recovery is often incomplete and can take months to years.
This is why the speed of osilodrostat’s cortisol-lowering effect matters. In both LINC 3 and LINC 4, cortisol reductions were described as rapid, not gradual over months. Faster cortisol normalization potentially means less cumulative neurotoxic exposure, though no study has yet directly measured cognitive outcomes as a primary endpoint in osilodrostat trials. That is a gap in the evidence worth acknowledging. Caregivers of patients with both Cushing’s and cognitive decline should be aware that cortisol normalization may initially feel worse before it feels better. Glucocorticoid withdrawal syndrome, which affected nearly 29 percent of patients in the ILLUSTRATE study, can produce fatigue, joint pain, and mood disturbances that overlap confusingly with dementia symptoms. Close communication with the treatment team during the dose-titration phase is essential to distinguish drug adjustment effects from neurological progression.
Why Expanded FDA Approval Changes the Treatment Conversation
Before April 2025, osilodrostat was approved only for Cushing’s disease, the specific subset caused by a pituitary adenoma. The expanded indication now covers all forms of endogenous hypercortisolemia in Cushing’s syndrome, including cases caused by adrenal tumors and ectopic ACTH-secreting tumors. This distinction matters because many patients with non-pituitary causes of Cushing’s previously had fewer pharmacological options and often faced off-label prescribing with less insurance support.
The broader label, supported by data from more than 350 patients across the development program, means endocrinologists can now prescribe osilodrostat with full FDA backing regardless of the underlying cause of cortisol excess. For the subset of patients who are elderly or who have comorbidities making surgery risky, which overlaps considerably with the population at highest risk for dementia, this expanded approval removes a bureaucratic barrier that could delay treatment. Every month of untreated hypercortisolism is a month of ongoing damage to the brain, cardiovascular system, and metabolic health.
What Comes Next for Non-Surgical Cushing’s Treatment
The rejection of relacorilant leaves osilodrostat as the clear frontrunner among recently approved options, but the Cushing’s treatment landscape is unlikely to remain static. Corcept Therapeutics may pursue additional clinical trials to address the FDA’s efficacy concerns, and other companies are investigating novel mechanisms of action targeting the HPA axis at various points. The success of osilodrostat has validated the concept that enzyme-level intervention in the adrenal gland can be both effective and tolerable for many patients, which may encourage further investment in this approach.
For patients and caregivers focused on brain health, the most important development to watch is whether future Cushing’s trials will begin incorporating cognitive endpoints alongside hormonal and metabolic ones. The link between cortisol normalization and neuroprotection is biologically sound, but it needs prospective clinical data to move from plausible inference to treatment guidance. In the meantime, osilodrostat represents the most direct and measurable way to reduce cortisol production without surgery, and for the brain, that reduction may be just as important as it is for the rest of the body.
Conclusion
Osilodrostat has earned its place as the standout non-surgical treatment for Cushing’s disease and, as of its expanded 2025 approval, Cushing’s syndrome broadly. It is the first drug to block the final enzyme in cortisol production, it has demonstrated 70 percent cortisol normalization in real-world use, and it offers clinicians a measurable, trackable treatment response. The rejection of relacorilant in late 2025 has, for now, reinforced osilodrostat’s position at the top of the non-surgical treatment hierarchy, though patients and physicians still have mifepristone, pasireotide, and levoketoconazole as alternatives depending on individual circumstances and tolerance profiles. For those navigating Cushing’s disease alongside concerns about cognitive decline, memory loss, or dementia risk, the central message is that cortisol control is brain protection.
Every day of normalized cortisol is a day the hippocampus is not under siege. Osilodrostat is not a perfect drug. Nearly one in three patients experiences adrenal insufficiency, and ongoing monitoring is non-negotiable. But it works, it works without surgery, and for a condition that has historically left patients with few good choices, that is a meaningful advance.
Frequently Asked Questions
Can osilodrostat reverse brain damage caused by Cushing’s disease?
Research suggests that cortisol normalization can partially reverse hippocampal atrophy and improve cognitive function, but recovery is often incomplete and may take months to years. Osilodrostat has not been studied with cognitive endpoints as a primary outcome, so the extent of neurological benefit remains an area for future research.
What is the most common dose of osilodrostat?
In real-world use from the ILLUSTRATE study, 64.3 percent of patients started at 2 mg twice daily, and about two-thirds of those who reached a maintenance dose remained at that level. However, dosing is individualized based on cortisol levels and tolerability.
Why was relacorilant rejected by the FDA?
The FDA issued a Complete Response Letter on December 30, 2025, stating it could not approve relacorilant without additional evidence of efficacy. The specifics of the disagreement between Corcept Therapeutics and the FDA have not been fully disclosed, though reporting has described the dispute as significant.
Is osilodrostat safe for elderly patients?
The expanded FDA approval does not exclude elderly patients, and the drug may be particularly relevant for older adults who are poor surgical candidates. However, the 28.6 percent rate of adrenal insufficiency reported in the ILLUSTRATE study warrants careful monitoring, especially in elderly patients who may be more vulnerable to the effects of cortisol fluctuations.
How does osilodrostat differ from mifepristone?
Osilodrostat reduces cortisol production by blocking the enzyme 11-beta-hydroxylase, so cortisol levels measurably decrease and can be tracked with standard lab tests. Mifepristone blocks the cortisol receptor without reducing production, which means blood cortisol levels actually rise during treatment, making monitoring more difficult. Mifepristone is also only approved for Cushing’s patients with hyperglycemia.
